To address this gap, we evaluated pCR rates according to sTIL levels and HG in patients with ER + HER2- breast cancer who received NAC, aiming to identify those who may benefit from chemoimmunotherapy and to explore predictive biomarkers. Here, ERBB2 is linked to breast carcinoma.